Modified FOLFOX6 (mFOLFOX6) in metastatic colorectal carcinoma patients with poor performance status

Tomohiro Nishi, Yasuo Hamamoto, Junko Uemoto, Kei Onodera, Etsuko Warita, Yasuhiro Yamanaka

研究成果: Article査読

1 被引用数 (Scopus)

抄録

Because mFOLFOX6 has few contraindications, it is useful for poor performance status (PS) cases. However, in Japan, there are some reports that the dose is reduced easily. We retrospectively examined the safety/usefulness of the full dose mFOLFOX6 (first-line) for advanced colon cancer patients with poor PS. Four of five cases had improved PS. The response rate was 60%. Grade 3/4 adverse events were infection, leukopenia, and neutropenia. Treatment-related deaths within 60 days of starting treatment were absent. Full-dose mFOLFOX6 for poor PS may be beneficial. However, we must consider the increased risk of adverse events.

本文言語English
ページ(範囲)2557-2560
ページ数4
ジャーナルJapanese Journal of Cancer and Chemotherapy
39
13
出版ステータスPublished - 2012 12

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

フィンガープリント 「Modified FOLFOX6 (mFOLFOX6) in metastatic colorectal carcinoma patients with poor performance status」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル